Allurion Technologies Holdings Inc. has released its preliminary, unaudited financial results for the second quarter of 2025, reporting revenue of approximately $3 million. The company also recorded an operating loss of about $7 million, showing an improvement compared to the operating loss of $9.3 million in the second quarter of 2024. This reduction in operating loss is partly attributed to a 50% decrease in operating expenses year-over-year. In strategic developments, Allurion is focusing on its R&D and clinical pipelines, emphasizing combination therapy and expanding its strategic distribution partnerships. The company has reported that clinics piloting the combination approach as part of a comprehensive obesity management program experienced a 20% growth in the second quarter of 2025 compared to the first quarter of the same year. Allurion has launched several initiatives, including a signed term sheet with a strategic partner to enhance its ex-US distribution and R&D pipeline. This includes the potential joint development of a novel, GLP-1 drug-eluting intragastric balloon. Additionally, the company has submitted a study protocol to European Institutional Review Boards for approval, focusing on combining the Allurion Program with low-dose GLP-1 for weight loss while maintaining muscle mass. Enrollment for this study is expected to begin within the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.